Cargando…
Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
BACKGROUND: Family planning is an important consideration for women with multiple sclerosis (MS), who are often diagnosed during their reproductive years. Currently, limited data are available on pregnancy outcomes in patients exposed to interferon-beta (IFN-beta) before or during pregnancy. Here, w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293672/ https://www.ncbi.nlm.nih.gov/pubmed/32100126 http://dx.doi.org/10.1007/s00415-020-09762-y |
_version_ | 1783546339418701824 |
---|---|
author | Hellwig, Kerstin Geissbuehler, Yvonne Sabidó, Meritxell Popescu, Catrinel Adamo, Alessandra Klinger, Joachim Ornoy, Asher Huppke, Peter |
author_facet | Hellwig, Kerstin Geissbuehler, Yvonne Sabidó, Meritxell Popescu, Catrinel Adamo, Alessandra Klinger, Joachim Ornoy, Asher Huppke, Peter |
author_sort | Hellwig, Kerstin |
collection | PubMed |
description | BACKGROUND: Family planning is an important consideration for women with multiple sclerosis (MS), who are often diagnosed during their reproductive years. Currently, limited data are available on pregnancy outcomes in patients exposed to interferon-beta (IFN-beta) before or during pregnancy. Here, we present the cumulative pregnancy exposure data and prevalence of pregnancy and infant outcomes in IFN-beta-exposed pregnant women with MS from the European IFN-beta Pregnancy Registry. METHODS: Using spontaneous and solicited reports, the registry collected data from 26 countries of the European Economic Area, consisting of information on women with MS identifying themselves to one of the Marketing Authorisation Holders (Bayer, Biogen, Merck KGaA, and Novartis) or healthcare professionals as pregnant and exposed to IFN-beta during pregnancy or within 1 month before conception. The outcomes collected by the registry included ectopic pregnancies, spontaneous abortions, elective terminations, live, and stillbirths with or without congenital anomalies. The prevalence of pregnancy outcomes was put in context with those reported in the general population. RESULTS: Between 2009 and 2017, the registry collected 948 pregnancy reports with a known pregnancy outcome. Overall, 82.0% (777/948) of pregnancies resulted in live birth without congenital anomaly. When comparing IFN-beta-exposed pregnancies with the general population, the prevalence of spontaneous abortions (10.7% vs. 10–21%) and congenital anomalies in live births (2.1% vs. 2.1–4.1%) were found to be within reported ranges. CONCLUSIONS: The data gathered from these pregnancy cases suggest no evidence that IFN-beta exposure before conception and/or during pregnancy adversely increases the rate of congenital anomalies or spontaneous abortions. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00415-020-09762-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7293672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-72936722020-06-16 Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry Hellwig, Kerstin Geissbuehler, Yvonne Sabidó, Meritxell Popescu, Catrinel Adamo, Alessandra Klinger, Joachim Ornoy, Asher Huppke, Peter J Neurol Original Communication BACKGROUND: Family planning is an important consideration for women with multiple sclerosis (MS), who are often diagnosed during their reproductive years. Currently, limited data are available on pregnancy outcomes in patients exposed to interferon-beta (IFN-beta) before or during pregnancy. Here, we present the cumulative pregnancy exposure data and prevalence of pregnancy and infant outcomes in IFN-beta-exposed pregnant women with MS from the European IFN-beta Pregnancy Registry. METHODS: Using spontaneous and solicited reports, the registry collected data from 26 countries of the European Economic Area, consisting of information on women with MS identifying themselves to one of the Marketing Authorisation Holders (Bayer, Biogen, Merck KGaA, and Novartis) or healthcare professionals as pregnant and exposed to IFN-beta during pregnancy or within 1 month before conception. The outcomes collected by the registry included ectopic pregnancies, spontaneous abortions, elective terminations, live, and stillbirths with or without congenital anomalies. The prevalence of pregnancy outcomes was put in context with those reported in the general population. RESULTS: Between 2009 and 2017, the registry collected 948 pregnancy reports with a known pregnancy outcome. Overall, 82.0% (777/948) of pregnancies resulted in live birth without congenital anomaly. When comparing IFN-beta-exposed pregnancies with the general population, the prevalence of spontaneous abortions (10.7% vs. 10–21%) and congenital anomalies in live births (2.1% vs. 2.1–4.1%) were found to be within reported ranges. CONCLUSIONS: The data gathered from these pregnancy cases suggest no evidence that IFN-beta exposure before conception and/or during pregnancy adversely increases the rate of congenital anomalies or spontaneous abortions. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00415-020-09762-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-02-26 2020 /pmc/articles/PMC7293672/ /pubmed/32100126 http://dx.doi.org/10.1007/s00415-020-09762-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Communication Hellwig, Kerstin Geissbuehler, Yvonne Sabidó, Meritxell Popescu, Catrinel Adamo, Alessandra Klinger, Joachim Ornoy, Asher Huppke, Peter Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry |
title | Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry |
title_full | Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry |
title_fullStr | Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry |
title_full_unstemmed | Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry |
title_short | Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry |
title_sort | pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the european interferon-beta pregnancy registry |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293672/ https://www.ncbi.nlm.nih.gov/pubmed/32100126 http://dx.doi.org/10.1007/s00415-020-09762-y |
work_keys_str_mv | AT hellwigkerstin pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT geissbuehleryvonne pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT sabidomeritxell pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT popescucatrinel pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT adamoalessandra pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT klingerjoachim pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT ornoyasher pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT huppkepeter pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry AT pregnancyoutcomesininterferonbetaexposedpatientswithmultiplesclerosisresultsfromtheeuropeaninterferonbetapregnancyregistry |